World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
71189
World Ranking
10639
National Ranking
1018

Overview

Paul Lorigan is affiliated with the University of Manchester in the United Kingdom. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Oncology, Molecular Biology, and Immunology. They have also contributed notably to Epidemiology and Cancer Research.

The scientist's main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Nonmelanoma Skin Cancer Studies

Frequent publication venues for their work are:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • British Journal of Dermatology

Frequent co-authors collaborating with Paul Lorigan include:

  • Paolo A. Ascierto
  • Georgina V. Long
  • Mario Mandalà
  • James Larkin
  • Caroline Robert

Selected recent papers authored or co-authored by Paul Lorigan include:

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo, 2020, JAMA Oncology
  • Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma, 2022, Nature Medicine
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022, 2022, European Journal of Cancer
  • Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial, 2020, Journal of Clinical Oncology

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Sandra P D'Angelo;James Larkin;Jeffrey A Sosman;Celeste Lebbé

  • Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

    James Larkin;David Minor;Sandra D'Angelo;Bart Neyns

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel

  • Revised U.K. guidelines for the management of cutaneous melanoma 2010.

    J.R. Marsden;J.A. Newton-Bishop;L. Burrows;M. Cook

  • Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

    Maria R. Girotti;Malin Pedersen;Berta Sanchez-Laorden;Amaya Viros

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

    Alexander M.M. Eggermont;Michal Kicinski;Christian U. Blank;Mario Mandala

  • Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

    Natalie J Ives;Rebecca L Stowe;Paul C Lorigan;Keith Wheatley

  • Revised UK guidelines for the management of cutaneous melanoma 2010

    J R Marsden;J A Newton-Bishop;L Burrows;M Cook

Frequent Co-Authors

James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Nick Thatcher
Nick Thatcher University of Manchester
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Mark R. Middleton
Mark R. Middleton University of Oxford
Claus Garbe
Claus Garbe University of Tübingen
Matteo S. Carlino
Matteo S. Carlino University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As medical careers evolve, many students look to online education for flexibility and affordability. There is a growing range of online healthcare degrees that open doors to rewarding roles outside traditional physician paths. For example, many aspiring healthcare professionals consider how much does it cost to become a medical coder. Medical coding is an entry point for those interested in healthcare administration and can be pursued entirely online at a lower cost compared to clinical degrees.

Nursing remains a top choice for those who want to work directly with patients. If budget is a concern, students often research cheap np programs to become Nurse Practitioners or explore cheapest bsn programs online for Bachelor of Science in Nursing options. Even advanced roles are accessible, such as obtaining a terminal degree through cheapest online dnp programs for a Doctor of Nursing Practice.

With diverse and affordable online pathways, students can tailor their educational journeys to fit both their career goals and financial needs.

Best Scientists Citing Paul Lorigan

Trending Scientists